Abbott Laboratories vs. Royalty Pharma plc Class A Ordinary Shares
ABT
Abbott Laboratories
$111.25 -0.02%
VS RPRXRoyalty Pharma plc Class A Ordinary Shares
$58.60 +0.07%
Royalty Pharma plc Class A Ordinary Shares (RPRX) comes out ahead, leading on 6 of 11 compared factors.
Size & Scale
| ABT | RPRX | |
|---|---|---|
| Market Cap | $191.92 billion | $26.37 billion |
| Revenue (TTM) | $46.59 billion | $2.54 billion |
| Net Income (TTM) | $5.42 billion | $1.35 billion |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | RPRX | |
|---|---|---|
| P/E Ratio | 36.00 | 31.17 |
| Price / Book | 3.71 | 2.69 |
| Price / Sales | 4.12 | 10.40 |
RPRX leads on 2 of 3 valuation factors.
Profitability
| ABT | RPRX | |
|---|---|---|
| Net Margin | 11.65% | 53.23% |
| Return on Equity | 10.48% | 13.79% |
RPRX leads on 2 of 2 profitability factors.
Dividend
| ABT | RPRX | |
|---|---|---|
| Dividend Yield | 2.27% | 1.60% |
| Payout Ratio | 81.55 | 50.00 |
ABT and RPRX split the dividend factors evenly.
Risk & Sentiment
| ABT | RPRX | |
|---|---|---|
| Short Interest | 0.57% | 0.34% |
RPRX leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, RPRX overview, RPRX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.
